TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of preventive care visits
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants With Serious Adverse Events (SAEs) and Non-Serious Adverse Events (NSAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With AEs Leading to Dose Modification or Study Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With AEs of Special Interest
Endpoint domain: Adverse events/effects
Primary endpoint: Change in myoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serious device or procedure-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of ICU admission
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Sex without a condom in the last 90 days
Endpoint domain: Adverse events/effects
Primary endpoint: No. of Late Severe GU Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: No. of Late Severe GI Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Gastric residence time (GRT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Vertebral side width of soft tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NYHA class deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total Gaviscon® tablets consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Catheter-related venous thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Decrease in GERD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Triglycerides and LDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Complete histological remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in medical ICU nurse fulfillment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Complete Response (no Vomiting and no Use of Rescue Therapy)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: parents' postnatal sense of security
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: time to reach diagnosis
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Procedure Safety: Adverse Event Assessment
Endpoint domain: Adverse events/effects
Primary endpoint: Family Empowerment Scale (FES)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Parent Sense of Competency (PSOC) Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Response of measurable lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Dynamic FDG PET imaging results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With the Development of ALT Donor Site Seroma
Endpoint domain: Adverse events/effects
Primary endpoint: Timing to Drain Removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: brain fMRI activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of children receiving a minimum acceptable diet
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: Natural history of subclinical atherosclerosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Immediate and delayed picture recognition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change From Baseline in Skin Health, Visual Skin Score (VSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of participants consenting to recruitment strategy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reduction of Thin-cap Fibroatheromas (TCFA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total Sign Score (TSS) at Week 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corrected count increment after platelet transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of subjects with an AC cell count of zero
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: No gastrointestinal rebleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Ascites disappear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Regulatory CD4+CD25+ T Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Suppressive Function of Expanded Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Immunologic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area under the curve (AUC0-12) of Raltegravir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration (Cmax) of Raltegravir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum concentration (Cmin) of Raltegravir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Craving for ATS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Heart Failure Related Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability and safety of the Influenza VLP Vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Degree of pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Peripheral PA2024 T-cell Proliferation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Acute physiology and chronic health evaluation IIScore
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bladder pressure changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Baseline Corrected FSH Area Under the Serum Concentration-time Curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Baseline Corrected FSH Maximum Serum Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Papilloma relapses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Head CT scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: brain MRI: with and without contrast
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of CMV pp65 specific CD8+ T cells produced
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Development of grade III-IV GVHD or major organ toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Restoration survival
Endpoint domain: Mortality/survival
Primary endpoint: Concentration of purine and pyrimidine in cord plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Image accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemagglutination inhibition (HI) immune responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: blood viscosity at shear rate 5/sec
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: hematocrit/blood viscosity at 5/sec
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Best Overall Clinical Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intestinal Microbial Diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Macrolide Resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Longitudinal DTI Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Pain Bowel Symptom Scale (BSS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Hippocampal Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: FEV1 Area Under Curve (AUC0-12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Baseline-Adjusted Average Predose FEV1 at End of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: 24 hour fluid balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Eligible New FP Clients Tested for HIV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean Maximum Temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective response rate (complete remission rate + partial remission rate)
Endpoint domain: Mortality/survival
Primary endpoint: Diagnostic value of post-processed SDCT images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurring cerebrovascular events
Endpoint domain: Mortality/survival
Primary endpoint: Plasma levels of angiogenic factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: maximum corneal curvature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of GSK2018682
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in retinal function of the macula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Presence of an anomaly in color fundus photography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Anomaly of retinal capillary density to OCT-A
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Changes in CrossFit-specific performance capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in energy substrates utilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glomerular Filtration Rate (GFR) mL/Min
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Seroconversion Rate 21 Days After the First Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroconversion Rate 21 Days After the Second Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Achieving an HI Antibody Titer of 1:40 or More 21 Days After the First Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Achieving an HI Antibody Titer of 1:40 or More 21 Days After the Second Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Decrease in number of Raynaud's attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: B wave latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: PhNR latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Magnitude of ffERG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: clearance or improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residual glucose percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Requiring Emergency General Anesthesia or Rescue Neuraxial
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients With Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline of muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from baseline of motor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Aphasia assessment score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Presence of neutrophils in sarcoma-affected tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Procedure and device related complication rate
Endpoint domain: Adverse events/effects
Primary endpoint: Freedom from stroke or death
Endpoint domain: Mortality/survival
Primary endpoint: Engagement in Smoking Cessation Treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Difference in infarct growth (PWI-DWI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in amount of worrying regarding memory impairment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of children with clinical malaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: apoptosis of cumulus cell
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of oral mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of oral pain of oral mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact of oral condition on the quality of life perceived by the children
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Slope of the decline in forced vital capacity (FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Investigator's Global Assessment (IGA) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: prevalence of alexithymia
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Implementation of sun safety practices and policy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Changes in reading performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in spelling performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Participants With Laboratory-Confirmed Clinical Influenza
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of neurosensory disturbance
Endpoint domain: Adverse events/effects
Primary endpoint: Quality from Patients Perspective
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Subject Assessment of Wrinkles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Independent Panel Global Improvement Assessment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean pain score during insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of olanzapine-induced weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: General Improvement Rating
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of patients with Dermatology Life Quality Index (DLQI)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: rate of change in implant stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Change in Glycosylated Haemoglobin A1c (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequency of use of decision aids
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Prevalence of SARS-CoV-2 antibody titres
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Biomarkers of aging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary Tumor Control at 2 Years
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Feasibility of stable DIBH performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in torque peak of quadriceps femoris
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change hamstring/quadriceps ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in HBA1c from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in Blood Flow Through the Vertebral Artery and Posterior Cerebral and Cerebellar Circulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Mild to Moderate Influenza Disease (MMID)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Treatment Emergent Adverse Events (TEAEs) Per Subject
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Treatment Emergent Adverse Event Classified by Relatedness and Severity
Endpoint domain: Adverse events/effects
Primary endpoint: proportion of patients in clinical remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quotient of psycho-motor development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tampon Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite renal outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: progression of CKD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean Menstrual Cramping Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Manchester-Oxford Foot Questionnaire Score (MOXFQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Mean Fridericia-Corrected QT (QTcF) Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Insulin transport into the CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Biochemically verified point prevalence abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to smoking relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: in-vivo anti-tumor response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in gait autonomy
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Parasitological failure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Patient Rated Tennis Elbow Evaluation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Saccadometry results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of CP-CML Participants With Major Cytogenetic Response (MCyR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of AP-CML Participants With Major Hematologic Response (MaHR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of BP-CML/Ph+ ALL Participants With MaHR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of uncovered stent struts per stent at follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Delivery at the facility of antenatal care enrollment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Early infant diagnosis testing 6-8 weeks after birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Prevalence of structural heart disease as cause of AV-block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of ischemic heart disease as cause of AV-block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of congenital heart disease as cause of AV-block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 28-day ACLF progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour narcotic consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Final refraction deviation from target
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of fatty acids in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Progression from Prediabetes to Diabetes
Endpoint domain: Mortality/survival
Primary endpoint: Geometric mean HI titer (GMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of subjects with HI titer ≥1:40
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes